Ellis, C N <br/><br/>
Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation.  [electronic resource] 

 -  Archives of dermatology  May 2000 
 - 609-16 p.  digital 
<br/><br/> Publication Type: Case Reports; Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0003-987X 
<br/><br/><label>Standard No.: </label>10.1001/archderm.136.5.609  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Animals<br/>Antineoplastic Agents--metabolism<br/>Cell Differentiation<br/>Chromans--metabolism<br/>DNA Primers<br/>Female<br/>Humans<br/>Keratinocytes--cytology<br/>Ligands<br/>Male<br/>Mice<br/>Mice, SCID<br/>Psoriasis--drug therapy<br/>RNA, Messenger--metabolism<br/>Receptors, Cytoplasmic and Nuclear--genetics<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Skin Diseases--drug therapy<br/>Thiazoles--metabolism<br/>Thiazolidinediones<br/>Transcription Factors--genetics<br/>Troglitazone